Chase Pharmaceuticals Overview
- Year Founded
-
2007
- Status
-
Acquired/Merged
- Employees
-
11
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$1B
Chase Pharmaceuticals General Information
Description
Provider of medications for the treatment of neurological and psychiatric diseases. The company focuses on the development of medications for the treatment of Alzheimer's disease.
Contact Information
Website
www.news.abbvie.comCorporate Office
- 1825 K Street
- Northwest Suite 510
- Washington, DC 20006
- United States
Corporate Office
- 1825 K Street
- Northwest Suite 510
- Washington, DC 20006
- United States
Chase Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | 22-Nov-2016 | $1B | Completed | Clinical Trials - Phase 2 | ||
| 5. Later Stage VC (Series B1) | 01-Jan-2017 | Completed | Clinical Trials - Phase 2 | |||
| 4. Later Stage VC (Series B) | 16-Mar-2016 | Completed | Clinical Trials - Phase 2 | |||
| 3. Later Stage VC (Series B1) | 16-Feb-2016 | Completed | Clinical Trials - Phase 2 | |||
| 2. Early Stage VC (Series A) | 16-Dec-2011 | $500K | $1.7M | Completed | Startup | |
| 1. Early Stage VC (Series A) | 15-Dec-2010 | $1.2M | $1.2M | Completed | Startup |
Chase Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B2 | ||||||||
| Series B1 | ||||||||
| Series A | 1,200,000 | $0.000100 | 8% | $1 | $1 | 1x | $1 | 6.86% |
Chase Pharmaceuticals Comparisons
Industry
Financing
Details
Chase Pharmaceuticals Competitors (76)
One of Chase Pharmaceuticals’s 76 competitors is NeuroNascent, a Venture Capital-Backed company based in Clarksville, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NeuroNascent | Venture Capital-Backed | Clarksville, MD | ||||
| Enterprise Therapeutics | Venture Capital-Backed | Brighton, United Kingdom | ||||
| Asceneuron | Venture Capital-Backed | Eysins, Switzerland | ||||
| Minerva Neurosciences | Formerly VC-backed | Burlington, MA | ||||
| Alzprotect | Venture Capital-Backed | Loos, France |
Chase Pharmaceuticals Patents
Chase Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3532060-A1 | Memantine combinations and use | Inactive | 28-Oct-2016 | ||
| EP-3532060-A4 | Memantine combinations and use | Inactive | 28-Oct-2016 | ||
| US-10548855-B2 | Memantine combinations and use | Inactive | 28-Oct-2016 | ||
| US-20180116979-A1 | Memantine combinations and use | Active | 28-Oct-2016 | ||
| US-20190269627-A1 | Memantine combinations and use | Inactive | 28-Oct-2016 | A61K31/13 |
Chase Pharmaceuticals Signals
Chase Pharmaceuticals Former Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Andera Partners | PE/Buyout | Minority | ||
| Brain Trust Accelerator Fund | Venture Capital | Minority | ||
| Cipla New Ventures | Impact Investing | Minority | ||
| New Rhein Healthcare | Venture Capital | Minority | ||
| Revolution (Washington DC) | Venture Capital | Minority |
Chase Pharmaceuticals FAQs
-
When was Chase Pharmaceuticals founded?
Chase Pharmaceuticals was founded in 2007.
-
Where is Chase Pharmaceuticals headquartered?
Chase Pharmaceuticals is headquartered in Washington, DC.
-
What is the size of Chase Pharmaceuticals?
Chase Pharmaceuticals has 11 total employees.
-
What industry is Chase Pharmaceuticals in?
Chase Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Chase Pharmaceuticals a private or public company?
Chase Pharmaceuticals is a Private company.
-
What is the current valuation of Chase Pharmaceuticals?
The current valuation of Chase Pharmaceuticals is .
-
What is Chase Pharmaceuticals’s current revenue?
The current revenue for Chase Pharmaceuticals is .
-
How much funding has Chase Pharmaceuticals raised over time?
Chase Pharmaceuticals has raised $38.2M.
-
Who are Chase Pharmaceuticals’s investors?
Andera Partners, Brain Trust Accelerator Fund, Cipla New Ventures, New Rhein Healthcare, and Revolution (Washington DC) have invested in Chase Pharmaceuticals.
-
Who are Chase Pharmaceuticals’s competitors?
NeuroNascent, Enterprise Therapeutics, Asceneuron, Minerva Neurosciences, and Alzprotect are some of the 76 competitors of Chase Pharmaceuticals.
-
When was Chase Pharmaceuticals acquired?
Chase Pharmaceuticals was acquired on 22-Nov-2016.
-
Who acquired Chase Pharmaceuticals?
Chase Pharmaceuticals was acquired by Allergan.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process